ArticleNeurobiology of aging2017
Interaction of APOE e4 and poor glycemic control predicts white matter hyperintensity growth from 73 to 76.
Article in Neurobiology of aging, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 12 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
12 citing papers in PubMed, 21 citations in OpenAlex.
- Role of white matter hyperintensity in effects of apolipoprotein E on cognitive injury.Frontiers in human neuroscience · 2023Review
- White matter hyperintensities in cholinergic pathways are associated with dementia severity in e4 carriers but not in non-carriers.Frontiers in neurology · 2023Article
- The relationship between diabetes-related cognitive dysfunction and leukoaraiosis.Acta neurologica Belgica · 2021Review
- Association between APOE e4 and white matter hyperintensity volume, but not total brain volume or white matter integrity.Brain imaging and behavior · 2020Article
- APOE-ε4 Genotype and Dementia Before and After Transient Ischemic Attack and Stroke: Population-Based Cohort Study.Stroke · 2020Article
- Spatial distribution and cognitive impact of cerebrovascular risk-related white matter hyperintensities.NeuroImage. Clinical · 2020Article
- Associations between vascular risk factors and brain MRI indices in UK Biobank.European heart journal · 2019Article
- Asymptomatic Cerebral Small Vessel Disease: Insights from Population-Based Studies.Journal of stroke · 2019Review
- Cohort Profile Update: The Lothian Birth Cohorts of 1921 and 1936.International journal of epidemiology · 2018Article
- Anserine/Carnosine Supplementation Preserves Blood Flow in the Prefrontal Brain of Elderly People Carrying APOE e4.Aging and disease · 2018Article
- Postprandial Hyperglycemia Is Associated With White Matter Hyperintensity and Brain Atrophy in Older Patients With Type 2 Diabetes Mellitus.Frontiers in aging neuroscience · 2018Article
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
15 authors at 5 institutions in 2 countries.
Funding
Abstract
We examined whether apolipoprotein E (APOE) status interacts with vascular risk factors (VRFs) to predict the progression of white matter hyperintensities (WMHs) on brain MRI scans over a specific period of life in older age when the risk of dementia increases. At age 73 years, baseline VRFs were assessed via self-reported history of diabetes, hypertension, smoking, and hypercholesterolemia, and via objective measures of blood HbA1c, body mass index, diastolic and systolic blood pressure, and blood high-density lipoprotein to total cholesterol (HDL) ratio. APOE e4 allele was coded as either present or absent. WMH progression was measured on MRI over 3 years in 434 older adults, in a same-year-of-birth cohort. APOE e4 carriers with either a self-reported diagnosis of diabetes (β = 0.160, p = 0.002) or higher glycated hemoglobin levels (β = 0.114, p = 0.014) exhibited greater WMH progression, and the former survived correction for multiple testing. All other APOE-VRF interactions were nonsignificant (β
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.